SPRY2 and prostate carcinoma: To investigate if SPRY2 and PTEN deficiencies may mediate CRPC, we used the genetically engineered mouse model of prostate cancer, Nkx3.1 Ptenfl/+Spry2fl/+ (hereafter referred as NPS) (Gao et al, 2012).